Medical Health & Life Science Research News

Research details developments in the global multiple system atrophy drugs pipeline therapeutics review

Multiple System Atrophy Pipeline Drugs and Therapeutics Review H1 2017 report provides descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.Report also reviews key companies AFFiRiS AG, Corestem Inc, Neuropore Therapies Inc, Prana Biotechnology Ltd and others involved in Multiple System Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.

- Agency -.

Multiple System Atrophy Pipeline Drugs and Therapeutics Review H1 2017 provide an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape. Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Complete 33 Pages PDF Report at: http://www.reportsnreports.com/contacts/.aspx?name=1057929 .

- Agency -.

Multiple System Atrophy (Central Nervous System) pipeline therapeutics guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 3 and 1 respectively.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat.

Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development Discussed: AFFiRiS AG, Corestem Inc, Neuropore Therapies Inc, Prana Biotechnology Ltd.

Multiple System Atrophy Drug Profiles Discussed: Anle-138b, CS-10BR05, ENT-01, NPT-20011, PBT-434, PD-01, PD-03, Small Molecules for Neurodegenerative Disease.

Report at www.reportsnreports.com/contacts/.aspx?name=1057929

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets DirectÂ’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope:

  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (Central Nervous System).
  2. The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  5. The pipeline guide reviews key companies involved in Multiple System Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  6. The pipeline guide evaluates Multiple System Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  8. The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (Central Nervous System).

Access Multiple System Atrophy - Pipeline Review H1 2017 Complete Report at www.reportsnreports.com/.aspx?name=1057929 .

List of Tables:

  1. Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2017
  2. Number of Products under Development by Companies, H1 2017
  3. Products under Development by Companies, H1 2017
  4. Number of Products by Stage and Target, H1 2017
  5. Number of Products by Stage and Mechanism of Action, H1 2017
  6. Number of Products by Stage and Route of Administration, H1 2017
  7. Number of Products by Stage and Molecule Type, H1 2017
  8. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by AFFiRiS AG, H1 2017
  9. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Corestem Inc, H1 2017
  10. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Neuropore Therapies Inc, H1 2017
  11. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Prana Biotechnology Ltd, H1 2017
  12. Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Discontinued Products, H1 2017.

List of Figures:

  1. Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2017
  2. Number of Products under Development by Companies, H1 2017
  3. Number of Products by Stage and Targets, H1 2017
  4. Number of Products by Stage and Mechanism of Actions, H1 2017
  5. Number of Products by Routes of Administration, H1 2017
  6. Number of Products by Stage and Routes of Administration, H1 2017
  7. Number of Products by Molecule Types, H1 2017
  8. Number of Products by Stage and Molecule Types, H1 2017

 

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.